NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES

1 . A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

Wherein:

X represents —CH 2 —, —NR 8 —, —O— or —S(O) n —;

R 1 represents CH 1-6 alkyl, C 2-6 alkoxy, CH 1-6 alkoxyCH 1-6 alkyl, hydroxyCH 1-6 alkyl, hydroxyC 1-6 alkoxy or hydroxyC 1-6 alkoxyC 1-6 alkyl;

R 2 represents hydrogen, C 1-6 alkyl or phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from R 6 ;

R 3 represents C 1-6 alkyl, C 1-6 alkoxy or —S—C 1-6 alkyl;

R 4 represents hydrogen, halogen, C 1-6 alkyl or C 1-6 alkoxy;

L 1 represents a direct bond, —(CR 9 R 10 ) m —, —CH═CH—(CR 9 R 10 ) q —, —C≡C—(CR 9 R 10 ) q —, —O—(CR 9 R 10 ) q —, —C(O)—O—(CR 9 R 10 ) q — or —O—(CH 2 ) q —NR 8 -(CH 2 ) q —;

R 5 represents methyl, hydroxy, —NR 11 R 12 , C 3-6 cycloalkyl, phenyl or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said phenyl and heterocyclic rings are optionally substituted with 1, 2 or 3 substituents selected from R 7 ;

R 6 represents C 1-6 alkyl, fluoroC 1-6 alkyl, C 1-6 alkoxy, hydroxy, halogen, cyano, —S(O) n —CH 1-6 alkyl or —CH 2 —C(O)—O—CH 1-6 alkyl;

R 7 represents C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxyC 1-6 alkyl, hydroxy, hydroxyC 1-6 alkyl or —(CH 2 ) q —NR 11 R 12 ;

R 8 represents hydrogen or C 1-6 alkyl;

R 9 and R 10 , identically or differently on each occurrence, represents hydrogen or methyl;

R 11 and R 12 independently represent hydrogen, C 1-4 alkyl or C 1-4 alkoxyC 2-4 alkyl;

m represents 1, 2, 3, 4, 5 or 6;

n represents 0, 1 or 2; and

q represents 0, 1, 2, 3, 4, 5 or 6;

with the proviso that the compound of Formula (I) is other than:

[3-(2-amino-4-methyl-6-pentylamino-pyrimidin-5-ylmethyl)]-benzoic acid ethyl ester;

methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-methoxybenzoate;

or

methyl 4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)-3-fluorobenzoate.

2 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X represents —CH 2 —.

3 . A compound according to claim 1 or claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents C 1-6 alkyl.

4 . A compound according to any one of claims 1 to 3 , or a pharmaceutically acceptable salt thereof, wherein R 2 represents hydrogen.

5 . A compound according to any one of claims 1 to 3 , or a pharmaceutically acceptable salt thereof, wherein R 2 represents phenyl wherein said phenyl is optionally substituted with 1, 2 or 3 substituents selected from R 6 .

6 . A compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, wherein R 3 represents methyl.

7 . A compound according to any one of claims 1 to 6 , or a pharmaceutically acceptable salt thereof, wherein R 4 represents C 1-6 alkoxy.

8 . A compound according to any one of claims 1 to 6 , or a pharmaceutically acceptable salt thereof, wherein R 4 represents hydrogen.

9 . A compound according to any one of claims 1 to 8 , or a pharmaceutically acceptable salt thereof, wherein R 4 is bonded at the ortho position of the phenyl ring relative to linkage —X—.

10 . A compound according to any one of claims 1 to 9 , or a pharmaceutically acceptable salt thereof, wherein q represents 1, 2 or 3.

11 . A compound according to any one of claims 1 to 10 , or a pharmaceutically acceptable salt thereof, wherein q represents 2 or 3.

12 . A compound according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt thereof, wherein L 1 represents —(CR 9 R 10 ) m —, —CH═CH—(CR 9 R 10 ) q — or —C≡C—(CR 9 R 10 ) q l —

13 . A compound according to any one of claims 1 to 11 , or a pharmaceutically acceptable salt thereof, wherein L 1 represents —O—(CR 9 R 10 ) q —.

14 . A compound according to any one of claims 1 to 13 , or a pharmaceutically acceptable salt thereof, wherein L 1 is bonded at the para position of the phenyl ring relative to linkage —X—.

15 . A compound according to any one of claims 1 to 13 , or a pharmaceutically acceptable salt thereof, wherein L 1 is bonded at the meta position of the phenyl ring relative to linkage —X—.

16 . A compound according to any one of claims 1 to 8 or 10 to 13 , or a pharmaceutically acceptable salt thereof, wherein L 1 is bonded at the ortho position of the phenyl ring relative to linkage —X—.

17 . A compound according to any one of claims 1 to 16 , or a pharmaceutically acceptable salt thereof, wherein R 5 represents NR 11 R 12 or a monocyclic 4, 5, 6 or 7 membered heterocyclic ring which comprises 1, 2 or 3 heteroatoms independently selected from O, N or S wherein said heterocyclic ring is optionally substituted with 1, 2 or 3 substituents selected from R 7 .

18 . A compound according to any one of claims 1 to 17 , or a pharmaceutically acceptable salt thereof, wherein R 5 represents NR 11 R 12 and R 11 and R 12 both represent methyl.

19 . A pharmaceutical composition which comprises a compound according to any one of claims 1 to 18 , or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.

20 . A compound according to any one of claims 1 to 18 , or a pharmaceutically acceptable salt thereof, for use as a medicament.

21 . A compound according to any one of claims 1 to 18 , or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

22 . Use of a compound according to any one of claims 1 to 18 , or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer.

23 . A method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the Formula (I), or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 18 .